利奈唑胺引起血液系统不良反应与临床安全用药  

Linezolid causes haematological adverse reactions and medication safety in clinical practice

作　　者：任晓蕾[1] 李婷婷[1] 张海英[1] 冯婉玉[1] 

机构地区：[1]北京大学人民医院药剂科,北京100044

出　　处：《中国新药杂志》2013年第5期605-608,共4页Chinese Journal of New Drugs

摘　　要：目的:以临床实例出发探讨利奈唑胺血液系统不良反应的发生特点,为临床用药安全提供依据。方法:报道应用利奈唑胺致白细胞、中性粒细胞、血小板三系血细胞进行性降低1例,并检索1979年至2012年国内医药期刊公开报道的利奈唑胺引起血液系统不良反应的病例,通过分析进一步论述利奈唑胺在临床应用的安全性问题。结果:利奈唑胺所致血液系统不良反应主要表现为血小板减少,通常为可逆反应,发生后及时停药,必要时做对症治疗可逐渐回升。结论:临床应重视利奈唑胺的用药安全问题,积极采取措施防范血液系统不良反应的发生。Objective：To investigate the characteristics of adverse drug reaction （ADR） of linezolid in hematologic system by analyzing clinical cases, and to provide reference for rational use of drugs. Methods：One case of white blood cells, neutrophil cells and platelet reduction induced by linezolid was reported. Literature about linezolid-induced hematologic system ADR reported in domestic pharmaceutical journals from 1979 to 2012 was collected and analyzed statistically. Safety issues of linezolid were further discussed. Results ： Linezolid-induced haema- tological adverse reactions mainly manifested thrombocytopenia. Blood cell reduction is usually reversible reaction. After the occurrence of adverse reactions, if we discontinue drug in time and give symptomatic treatment when necessary, blood cells may pick up gradually. Conclusion：More attention should be paid to avoid and reduce the occurrence of hematologic system ADR induced by linezolid.

关 键 词：利奈唑胺 血液系统 不良反应 安全用药 

分 类 号：R974[医药卫生—药品]